The U.S. Food and Drug Administration (FDA) is not expected to move quickly on regulating cannabinoids (CBD) from hemp, Cowen analyst Harrison Vivas said in a research note on Wednesday. “We are encouraged by increasing numbers of studies and greater regulatory focus relative to even five years ago, but we still do not expect to see a near-term change in the FDA’s treatment of CBD in ingestible formats without pressure from Congress,” Vivas said. Vivas’s comments came after the FDA held a meeting Tuesday with The Science Board to the Food and Drug Administration to consider challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity, using cannabinoids as a case study
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
